Results 211 to 220 of about 38,631 (238)
Some of the next articles are maybe not open access.
[Novel indications for phosphodiesterase type 5 inhibitors].
Medizinische Klinik (Munich, Germany : 1983), 2007Phosphodiesterase type 5 (PDE5) induces the breakdown of cyclic guanosine monophosphate (cGMP) in smooth muscle cells. Hence, PDE5 inhibitors promote vasodilative effects by enhancing intracellular cGMP levels. Three PDE5 inhibitors, sildenafil, vardenafil, and tadalafil, have been approved for the treatment of "erectile dysfunction" (ED).
Stephan, Rosenkranz +2 more
openaire +1 more source
New Avenues for Phosphodiesterase Inhibitors in Asthma
Journal of Experimental Pharmacology, 2021Maria Gabriella Matera +2 more
exaly
The use of phosphodiesterase type 5 inhibitors for erectile dysfunction
Current Opinion in Urology, 2004MONTORSI, FRANCESCO +4 more
openaire +3 more sources